Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables

Author:
  • HK Johannsdottir
  • G Johannesdottir
  • BA Agnarsson
  • H Eerola
  • A Arason
  • OT Johannsson
  • P Heikkila
  • V Egilsson
  • Håkan Olsson
  • Åke Borg
  • H Nevanlinna
  • RB Barkardottir
Publishing year: 2004
Language: English
Pages: 2681-2687
Publication/Series: Anticancer Research
Volume: 24
Issue: 5A
Document type: Journal article
Publisher: International Institute of Cancer Research

Abstract english

Background: Chromosomal aberrations in breast tumors from BRCA1 and BRCA2 germ-line mutation carriers are considerably more frequent than what is seen in sporadic breast tumors. According to Comparative Genomic Hybridisation analysis (CGH), deletions on chromosome 4 are one of the most frequent events in BRCA1-associated tumors, suggesting inactivation of specific tumor suppressor genes. Materials and Methods: In the present study, 16 microsatellite markers covering chromosome 4 were used to map loss of heterozygosity (LOH) in tumors from BRCA1 (n =41) as well as in tumors from BRCA2 (n = 66) mutation carriers and in tumors from unselected cases of breast cancer (n = 68). Results: The frequency of LOH in these groups ranged from 16-73% in BRCA1-associated tumors, 13-42% in BRCA2-associated tumors and 8-33% in unselected tumors. LOH was significantly more frequent in BRCA1-associated tumors as compared to BRCA2-associated tumors and unselected tumors, and particularly high (over 70%) at 4q35.2. Pathological variables that were found significantly associated (pless than or equal to0.05) with LOH at specific markers were: high percentage of cells in S-phase, negative estrogen receptor status, young age at diagnosis and large tumors. Deletion mapping indicates the existence of seven non-overlapping regions at chromosome 4, which were identified in all three groups of tumors. Three of these seven regions, 4p16.3-p16.1, 4q27-q32.1 and 4q35.1-4qter, have not been reported in breast cancer previously. Conclusion: The results manifest the frequent alterations of chromosome 4 in BRCA1-associated breast tumors and indicate the location of several genes of potential importance in breast cancer development.

Keywords

  • Cancer and Oncology
  • BRCA2
  • breast cancer
  • BRCA1
  • loss of heterozygosity

Other

Published
  • ISSN: 1791-7530
Åke Borg
Åke Borg
E-mail: ake [dot] borg [at] med [dot] lu [dot] se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2

90

Project manager

Familial Breast Cancer

90

Professor

Oncology and Pathology, MV

MV 404 C21C2

90